Akili, Inc. (NASDAQ: AKLI), relating to its proposed merger with Vital Therapeutics Corporation. Under the terms of the agreement, Vital Therapeutics Corporation will acquire all the outstanding shares of Akili common stock for $0.4340 cash per share.